logo
America is sinking, and Canada cannot go down with the ship

America is sinking, and Canada cannot go down with the ship

Globe and Mail19 hours ago
Claude Lavoie is a contributing columnist for The Globe and Mail. He was director-general of economic studies and policy analysis at the Department of Finance from 2008 to 2023.
Here we are. Wednesday is the deadline for countries to sign new trade deals with the United States, or face punishing tariffs. The European Union seems confident it will reach a deal, though the outlook does not look so rosy for others. U.S. President Donald Trump has threatened 25-per-cent tariffs on Japan and Korea if they don't come to heel.
As the clock ticks down, it's worth noting the irony: Mr. Trump is blaming other countries for the large U.S. trade deficits when the U.S. should be looking at itself.
This trade war – plus the passing of the 'Big Beautiful Bill' last week and the associated boost in spending – suggests it's unlikely Americans will do the appropriate work to address their issues. And while trade deficits are not inherently good or bad, these continuous large deficits will end up disturbing financial and currency markets, creating challenges and opportunities for Canada.
A trade deficit occurs when a country imports more than it exports, or essentially when Americans spend more than they earn.
Analysis: The U.S. midterm campaigns will test whether Trump has truly set electoral politics on a new course
To make up the difference, the U.S. economy borrows from foreign investors by selling them government or corporate bonds, stocks, real estate and other instruments. The accumulation of trade deficits over the years mean that the U.S. is heavily indebted to other countries. On a net basis (accounting for what is owed by other countries to the U.S.), Americans owe the rest of the world US$26-trillion – 90 per cent of the U.S. GDP. This is the largest net foreign debt of any advanced economy.
Normally such a high level of foreign debt would worry financial markets. Investors would start dumping U.S. assets, which would lead to a U.S. dollar depreciation and higher interest rates for American borrowers. However, Americans have increased their foreign debt with impunity because the U.S. dollar is the world's reserve currency.
Indeed, some might say the chicken comes before the egg: The U.S. spends more than it produces precisely because it attracts so much foreign money. Needing U.S. dollar-denominated assets to pay for their international transactions, foreign investors are willing to turn a blind eye to the country's excessive spending.
This is America's so-called 'exorbitant privilege' that provides the U.S. with lower costs of borrowing, cheaper import prices and power over the global financial system. This privilege certainly incentivizes Americans to become more indebted, but just because you have a line of credit with a very low interest rate doesn't mean you should max it out.
Through years of abusing its privilege, the United States has eroded confidence in its dollar. According to a CFA Institute survey, close to two-thirds of global financial professionals expect that the greenback will lose its leading reserve-currency status in the next five to 15 years. The global selloff of American bonds last month suggests the U.S. administration's chaotic actions may have accelerated this timeline.
Marcus Gee: How Trump could make Canada better
One might expect that a combination of tariffs, drastic public spending cuts, and a potential Mar-a-Lago accord (designed to devalue the dollar) will correct this problem. Drastic public spending cuts, such as those announced by DOGE, might help but are unlikely to be large enough. Any significant fiscal deficit reduction will require cuts in social programs because, as in Canada, most government outlays are transfers to individuals.
Such cuts will increase poverty and inequality rates, which are already among the highest in the industrialized world, and risk leading to social unrest. The debate around last week's 'Big Beautiful Bill' shows how difficult it will be to bring spending to a level compatible with a reasonable deficit.
Tariffs increase consumer prices and reduce spending, reducing borrowing needs. However, tariffs also increase the costs of inputs and production and make other countries retaliate. These lead production and income to fall, increasing borrowing needs.
Raising individual taxes is one potential effective solution. But Mr. Trump is doing the opposite to satiate the rich oligarchy supporting his administration.
This means the amount of debt the U.S. owes will continue to pile up. This and political dysfunction are significantly threatening the position of the greenback as the world's reserve currency and raising the risk of a global currency realignment. We can expect the U.S. to gradually lose its financial power and the U.S. dollar to weaken.
When foreign investors sell their U.S. assets, will they invest the proceeds in Canada or somewhere else? This will depend on how financial markets perceive our country, particularly our ability to decouple from the U.S. economy. The fact that the Canadian dollar has remained relatively weak suggests the market is not too optimistic about our ability to do so.
The new federal government has a marketing job to do. Canada is well positioned. Our fiscal situation is relatively sound, at least for now. Canadians are net lenders to the rest of the world. Our inequality and poverty rates are relatively low. Even if we're cut off from the U.S. market, Canadian businesses still benefit from 15 free-trade agreements and preferential access to 50 markets representing a third of the global economy. A company setting up in Canada has access to all these markets and will likely have better access to the U.S. market than if it goes somewhere else.
The current trade war presents challenges and opportunities for Canada. Further improving our investments and economic framework would make Canada more attractive for human and physical capital losing faith in the U.S. We need to show we can be economically independent and able to withstand what is looking like the gradual fall of the American empire.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

Globe and Mail

time21 minutes ago

  • Globe and Mail

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry 's decline of 2.2%. The stock has also outperformed the sector and the S&P 500 index in this time frame. Gilead Outperforms Industry, Sector & S&P 500 Index It has been an eventful year for GILD so far. The company recently obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. This groundbreaking injectable therapy marks the first and only twice-yearly pre-exposure prophylaxis (PrEP) option available in the United States. Let's delve further into GILD's strengths and weaknesses to analyze how to play the stock at present. Lenacapavir Approval Boosts GILD's HIV Franchise Gilead has a market-leading portfolio of HIV treatments. Flagship drug Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum. Descovy (FTC 200 mg/TAF 25 mg) for PrEP is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States. The recent FDA approval of lenacapavir under the brand name Yeztugo solidifies GILD's HIV portfolio as its other prevention drug, Truvada, faces generic competition. At present, there are two FDA-approved daily oral medications for PrEP — Truvada and Descovy. As the first long-acting injectable PrEP administered just twice a year, Yeztugo addresses persistent barriers, such as challenges with daily oral PrEP, adherence, stigma and healthcare access, which have limited broader PrEP adoption. This approval also represents a paradigm shift in HIV prevention and is expected to catalyze uptake among populations that have historically been underserved by existing prevention tools. Yeztugo has a competitive advantage as it needs to be taken only twice a year, unlike daily oral pills, and addresses a broad population. The European Medicines Agency has also validated the Marketing Authorization Application for twice-yearly lenacapavir for HIV prevention. Livdelzi Strengthens GILD's Liver Disease Portfolio GILD's diverse portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases. The FDA approval of seladelpar for the treatment of primary biliary cholangitis (PBC) has strengthened GILD's liver disease portfolio and validated its CymaBay acquisition. The drug's initial uptake is encouraging. The candidate was approved under the brand name Livdelzi. Gilead also recently received conditional marketing authorization from the European Commission for seladelpar for the treatment of PBC. Challenges for GILD's Oncology Business Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025. Breast cancer drug Trodelvy's sales were lower than expected in the first quarter due to inventory dynamics. Nonetheless, Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in progression-free survival in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors. The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line mTNBC in 2026 will strengthen the company's oncology business. GILD's Valuation and Estimate Revision According to the price/earnings ratio, GILD's shares currently trade at 13.62x forward earnings, lower than the large-cap pharma industry's average of 15.01X but higher than its mean of 10.52X. Earnings estimates for GILD have moved north in the past 60 days. The bottom-line estimate for 2025 has inched up to $7.92 from $7.91, while that for 2026 has improved to $8.48 from $8.39. Invest in GILD Large biotech companies are generally considered safe havens for investors interested in this sector as they are well-equipped to weather the uncertain macroenvironment. Gilead's efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. The approval of Yeztugo for PrEP is a major boost for the company. GSK's HIV portfolio sales are being driven by strong patient demand for Cabenuva, Apretude and Dovato. GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. Gilead's strategic deals and acquisitions to diversify its business are encouraging. We recommend the stock to prospective investors, as we believe there is more room for growth following Yeztugo approval, even though Biktarvy sales are expected to be under pressure due to the redesign of Medicare Part D. Another positive factor for both prospective and existing investors is the company's attractive dividend yield. Gilead has been consistently increasing and paying out dividends. The company declared a quarterly dividend of $0.79 per share of common stock for the second quarter of 2025. Its strong cash position (as of March 31, 2025, GILD had $7.9 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 2.83% is sustainable. Gilead presently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Toronto saw lowest rent growth of all major Canadian cities in 2024: report
Toronto saw lowest rent growth of all major Canadian cities in 2024: report

CTV News

time30 minutes ago

  • CTV News

Toronto saw lowest rent growth of all major Canadian cities in 2024: report

Condominiums and the CN Tower are shown along the Toronto skyline on Tuesday, April 25, 2017. THE CANADIAN PRESS/Cole Burston Toronto saw the lowest rent growth among all major urban centres across the country in 2024 due, in part, to rising vacancy rates in the city, a new report has found. Released by the Canadian Mortgage and Housing Corporation on Tuesday, the Fall 2024 Rental Market Report showed that for purpose-built rental apartments in the city, rent rose by 2.4 per cent annually in 2024 for a two-bedroom unit, down from 8.7 per cent a year earlier. 'Toronto had the lowest rent growth among major (Census Metropolitan Areas). This is the result of rising vacancy rates and a low turnover rate, which declined further in 2024. For occupied units under rent control, landlords had limited ability to raise rents beyond the provincial guideline,' it read. 'Moreover, with a record increase in the supply of rental apartment condominiums, landlords in the purpose-built sector prioritized keeping existing tenants by taking a more cautious approach to rent increases.' According to the report, the vacancy rate for purpose-built rentals in Toronto rose to 2.3 per cent in 2024, slightly higher than the 10-year historical average. 'An elevated number of condominium projects were completed in the City of Toronto over the past year, with 45% of their units rented out,' it noted. 'This led to a significant influx of condominium rentals in the area, providing much greater choice to renters. Faced with more competition, new purpose-built rental units remained vacant for longer, according to local market intelligence.' In and around Toronto's downtown core, there was an average annual rent reduction of about one per cent for condo apartments, the report said. Vacancy rates were also higher in suburban areas of the GTA, including Durham, York, Peel, and Halton regions. According to the report, those areas saw a 3.3 per cent vacancy rate for purpose-built rentals as 'supply outpaced growth in demand.' The report states that vacancy rates are expected to rise in most major markets in 2025. 'Sluggish job markets and decelerating migration are creating challenging environments for landlords and property managers,' it said. According to the report, while the slower rent growth in Toronto represents 'a modest improvement in rental affordability following years of erosion,' affordability challenges persist in the city. For more affordable units, turnover reached a 'new low,' as existing tenants face a 28 to 43 per cent premium to rent a vacant unit at the market rate, the report notes. 'Supply remained scarce for low-income renters, with a vacancy rate of only 0.4% for the least expensive units,' the report said.

Cal-Maine Foods, Inc. Announces Release Date for Fourth Quarter and Fiscal 2025 Results
Cal-Maine Foods, Inc. Announces Release Date for Fourth Quarter and Fiscal 2025 Results

Globe and Mail

time36 minutes ago

  • Globe and Mail

Cal-Maine Foods, Inc. Announces Release Date for Fourth Quarter and Fiscal 2025 Results

Cal-Maine Foods, Inc. (NASDAQ: CALM) today announced that the Company will release its fourth quarter and fiscal 2025 financial results on Tuesday, July 22, 2025. A press release will be issued after the close of market trading. About Cal-Maine Foods Cal-Maine Foods, Inc. is primarily engaged in the production, packaging, marketing and distribution of fresh shell eggs, including conventional, cage-free, organic, brown, free-range, pasture-raised and nutritionally enhanced eggs, as well as a variety of egg products and prepared foods. The Company, which is headquartered in Ridgeland, Mississippi, is the largest producer and distributor of fresh shell eggs in the nation and sells most of its shell eggs throughout the majority of the United States.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store